These promising results—from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile ...
Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET ® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results